Enamines
Medchemexpress LLC To-1187 TFA | 98.4% | 795.72 | 100 MG
TO-1187 TFA is a selective HDAC6 PROTAC degrader with a DC50 of 5.81 nM. It functions by promoting the ubiquitination and degradation of HDAC6 and can be used in the study of hematological malignancies and solid tumors. The compound is described as being composed of an HDAC6 ligand (HY-173386), a CRBN ligase ligand (HY-41547), and a linker (HY-140212).
- Selective HDAC6 PROTAC degrader (DC50: 5.81 nM).
- Promotes the ubiquitination and degradation of HDAC6.
- Applicable in the study of hematological malignancies and solid tumors.
Medchemexpress LLC To-1187 (TFA) | 98.4% | 795.72 | 50 MG
TO-1187 TFA is a selective HDAC6 PROTAC degrader with a DC50 of 5.81 nM. It functions by promoting the ubiquitination and degradation of HDAC6. This compound is suitable for use in research studying hematological malignancies and solid tumors. The compound is composed of an HDAC6 ligand, a CRBN ligase ligand, and a linker.
- Selective HDAC6 PROTAC degrader, exhibits a DC50 of 5.81 nM, indicating potent and specific degradation of HDAC6.
- Promotes ubiquitination and subsequent degradation of HDAC6.
- Useful in the study of hematological malignancies and solid tumors.
- Consists of a specific HDAC6 ligand, a CRBN ligase ligand, and a linker.
- Purity of 98.41%.
Medchemexpress LLC (S)-Nimodipine | 77940-93-3 | 99.9% | 418.44 | 1 MG
(S)-Nimodipine is an enantiomer of Nimodipine, a light-sensitive dihydropyridine calcium antagonist. This orally active and well-tolerated compound is utilized in the research of cerebrovascular disorders.
- Enantiomer of Nimodipine
- Orally active
- Dihydropyridine calcium antagonist
- Target: Calcium channel
- Pathway: Membrane transporter/ion channel; neuronal signaling
- Appearance: White to off-white solid
- Purity: 99.9%
- Molecular formula: C21H26N2O7
eMolecules 39741-62-3 | tert-butyl (2S)-2,5-diamino-5-oxopentanoate hydrochloride | Synthonix - Stock | MFCD00039081 | 238.710 | C9H19ClN2O3 | 95.000 | Cl.CC(C)(C)OC(=O)[C@@H](N)CCC(N)=O | 25g | 495874754
tert-butyl (2S)-2,5-diamino-5-oxopentanoate hydrochloride | Synthonix - Stock | 39741-62-3 | MFCD00039081 | 238.710 | C9H19ClN2O3 | 95.000 | Cl.CC(C)(C)OC(=O)[C@@H](N)CCC(N)=O | 25g | 495874754
Accela Chembio Inc Isopropyl 3-aminocrotonate | 100g | 14205-46-0 | MFCD00134272 | 97+% | Shelf Life: 1260 Days | Light Sensitive/+4
Isopropyl 3-aminocrotonate | 100g | 14205-46-0 | MFCD00134272 | 97+% | Shelf Life: 1260 Days | Light Sensitive/+4
Medchemexpress LLC CDK2-IN-4 | 1316652-41-1 | 99.3% | 326.37 g/mol | C16H14N4O2S | 5 MG
NCC-149 is a selective histone deacetylase 8 (HDAC8) inhibitor used in cell biology research, including studies of neural differentiation. The product is provided with supporting documentation for purity, handling, and storage, and is available both as a solid and as a DMSO solution.
- Selective HDAC8 inhibitor for neural differentiation studies.
- Documented purity approximately 99.3% based on certificate of analysis.
- Available as a solid and as a 10 mM solution in DMSO.
- Datasheet, certificate of analysis, and safety data sheet provided for quality and safety information.
- Storage recommendations included for powdered material and solutions.
Medchemexpress LLC PF-562271 besylate | 939791-38-5 | MFCD14105612 | 99.2% | 665.66 | C27H26F3N7O6S2 | 50 MG
PF-562271 besylate is the besylate salt of a potent, ATP-competitive, reversible inhibitor of focal adhesion kinase (FAK) and Pyk2 commonly used in preclinical biochemical and cellular research. It shows low-nanomolar activity against FAK and is supplied at high purity in small-scale packages for laboratory studies.
- Potent ATP-competitive inhibitor of FAK and Pyk2 (FAK IC50 ≈ 1.5 nM; Pyk2 IC50 ≈ 13 nM).
- Reversible mechanism suitable for biochemical assays.
- High purity for research applications (reported ~99.17%).
- Available in multiple small-scale package sizes for laboratory use.
- Suitable for cellular and signaling pathway studies.
Medchemexpress LLC Molibresib (besylate) | 1895049-20-3 | 97.0% | 50 MG
Molibresib besylate is an orally active pan-BET inhibitor that targets BRD2, BRD3, BRD4, and BRDT. It disrupts the interaction between BET proteins and chromatin, inhibiting MYC expression and target gene transcription. This compound exhibits broad antiproliferative activity, inhibiting cancer cell growth and inducing growth arrest. It is widely applicable to research related to acute myeloid leukemia, multiple myeloma, triple-negative breast cancer, small-cell lung cancer, and various advanced refractory solid tumors.
- Orally active pan-BET inhibitor.
- Targets BRD2, BRD3, BRD4, and BRDT.
- Inhibits MYC expression and target gene transcription.
- Exhibits broad antiproliferative activity.
- Shows synergistic effect with MEK inhibitors.
- Applicable for research in acute myeloid leukemia, multiple myeloma, triple-negative breast cancer, and small-cell lung cancer.
Selleck Chemical LLC Amlodipine Besylate S1813-1g
Amlodipine Besylate is a long-acting calcium channel blocker used to lower blood pressure and prevent chest pain
Selleck Chemical LLC Nimodipine S1747-1g
Nimodipine (BAY E 9736) is a dihydropyridine calcium channel blocker and an autophagy inhibitor used in the treatment of high blood pressure
Selleck Chemical LLC PF-562271 Besylate S2672-1g
PF-562271 Besylate is the benzenesulfonate salt of PF-562271 which is a potent ATP-competitive reversible inhibitor of FAK with IC50 of 1 5 nM 10-fold less potent for Pyk2 than FAK and 100-fold selectivity against other protein kinases except for some CDKs Phase 1
Medchemexpress LLC Amlodipine Besylate, USP | 111470-99-6 | MFCD00887594 | >=98% | 1 G
Amlodipine besylate is an antianginal agent and an orally active dihydropyridine calcium channel blocker. It functions by blocking voltage-dependent L-type calcium channels, which inhibits the initial influx of calcium. This compound is suitable for research related to high blood pressure and cancer.
- Antianginal agent: Used in research for angina.
- Orally active: Convenient for oral administration in research settings.
- Dihydropyridine calcium channel blocker: A specific type of calcium channel blocker with a well-defined mechanism of action.
- Mechanism of action: Blocks voltage-dependent L-type calcium channels, inhibiting calcium influx.
- Versatile research applications: Applicable for research concerning high blood pressure and cancer.